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Basic research
Prions continue to pose a formidable challenge to life sci-
ences. While human prion diseases are still rare, the inci-
dence of a new variant of Creutzfeldt-Jakob disease in
the United Kingdom is increasing exponentially—raising
fears that it might develop into a major epidemic. This
disease is likely to represent the result of human infec-
tion with bovine prions. Therefore, understanding how
prions replicate and damage the brain, and how their
action may be possibly counteracted, has become a major
public health issue. Here I examine some current hypothe-
ses concerning the links between bovine and human prion
diseases, and the mechanisms by which prions reach and
damage the central nervous system after having entered
the body at extracerebral sites. 
wenty years after the inferred beginning of the
bovine spongiform encephalopathy (BSE) epidemic,
1,2
in-depth understanding of the impact of this zoonosis
on human health has become more important than ever.
As far as the actual status of BSE today goes,the news is
mixed but not uniformly bad: the incidence of this dis-
ease within the British “national herd” (the total cattle
population in the United Kingdom) reached a peak in
1992,and has declined ever since.
2,3The first histopatho-
logical confirmation of BSE was reported in November
1986 for a case that had occurred in April 1985. Conta-
minated meat-and-bone meal (which had been used as a
protein supplement in ruminant feed) was soon recog-
nized as the predominant mode of transmission of the
disease;this feeding practice was banned in 1988.
Given the average incubation time of the disease—which
runs to several years—one could argue that the mea-
sures introduced were highly effective.However,there is
much less reason to rejoice when one considers that sev-
eral mathematical models proposed in the past few years
predicted that the prevalence of the disease would level
off to zero around the turn of the century—a prediction
that has unfortunately proved untrue (Figure 1).
4
Switzerland,the country in which the authors of this arti-
cle work, has the dubious privilege of being the nation
with the largest number of reported BSE cases after the
United Kingdom, Portugal, and Ireland.
5 Although the
peak of the epidemic hit Switzerland some 3 years after
it hit the United Kingdom,it has leveled off to relatively
low but stable levels in the last 24 months.Of even more
concern is the fact that in at least one country,ie,Portugal
(as well as—at least formally—Ireland and France), the
number of BSE cases is actually increasing.
6,7
BSE and human prion diseases
While all of the above may be predominantly of con-
cern to veterinary medicine, a peculiar new variant of
Creutzfeldt-Jakob disease (CJD,the pendant to BSE in
humans) was first described in 1996
8 and has, thus far,
taken a toll of 83 lives (Table I).
9As detailed below,there
is good reason to suspect that new-variant Creutzfeldt-
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Jakob disease (nvCJD) represents the result of infec-
tion of humans with the BSE agent.
Several striking characteristics of nvCJD set it aside
from the “classical” sporadically occurring Creutzfeldt-
Jakob disease (sCJD) that was described eight decades
ago (Table II).
10,11 For one thing, sCJD typically affects
elderly persons, whereas nvCJD has so far predomi-
nantly hit very young people,with an age range spanning
between 12 and 52 years.The reason for this age distri-
bution remains unclear.
12Also,the clinical course of the
two diseases is radically different: sCJD is typically a
rapidly progressing illness leading to severe dementia
and ultimately death within months,and sometimes even
weeks.On the other hand,nvCJD tends to develop over
a much more protracted period.Also, the predominant
initial symptoms in nvCJD are personality changes and
psychosis,rather than dementia.
13
Even under the microscope,the two diseases are very dif-
ferent from each other.sCJD is typically characterized by
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Figure 1. Confirmed cases of bovine spongiform encephalopathy (BSE) plotted by month and year of onset. Data valid to end of January 2000
(produced in June 2000). The good news is that the epizootic has been receding ever since 1992. The not-so-good news is that, despite
several predictions, the incidence has not reached zero, and appears to be leveling off asymptotically at a low, but measurable, height.
Reproduced from reference 3: http://www.maff.gov.uk/animalh/bse/bse-statistics/graph/epidem.pdf. Copyright © 2000, Ministry of Agricul-
ture, Fisheries and Food, UK. Recent developments in prion diseases - Aguzzi Dialogues in Clinical Neuroscience - Vol 3 . No.1 . 2001
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widespread vacuolation of the cortical neuropil, which,
in its most extreme manifestation,makes the brain resem-
ble a sponge (when observed under low-magnifica-
tion microscopy), hence the designation “spongiform
encephalopathy.” Instead, the hallmark of nvCJD is the
extremely prominent accumulation of small spherical pro-
tein deposits,termed plaques,in the brain of the affected
individual.While some plaques can be seen in a minority
of patients affected with sCJD,the plaques of nvCJD have
a specific morphology that includes a characteristic rim
of microvacuolated tissue.Further peculiarities of nvCJD
include severe destruction of neurons in the thalamus,
which is recognizable by noninvasive neuroimaging meth-
ods (the so-called pulvinar sign),
14 as well as generalized
colonization of the lymphoid organs by the infectious
agent and deposition of the disease-associated prion pro-
tein (PrP) known as PrP
Sc (see below) in the germinal cen-
ters of the lymph nodes,tonsils,and spleen.
15-17
Finally, the new disease has so far exclusively struck
patients whose prion gene homozygously encodes
methionine at position 129.This group represents only
one third of the population
18 and approximately two
thirds of sCJD patients in the authors’ experience.
For the sake of completeness,it has to be said that CJD
of very young people is not a totally new phenomenon.
In the last 20 years,development of the disease has been
recorded in almost 100 children and teenagers. How-
ever,in the overwhelming majority of cases,this was the
result of documented iatrogenic exposure to the agent,
typically brought about by administration of growth
hormone or pituitary gonadotrophins of cadaveric ori-
gin,which had been (sometimes liberally) administered
to treat pituitary dwarfism and other conditions in the
era preceding recombinant DNA technology.
What are the lines of evidence that the agent causing
nvCJD is identical to that of BSE when transmitted to
humans? None of the arguments that have surfaced to
date are completely conclusive—yet each of them is cer-
tainly tantalizing, particularly when all are considered
together. For one thing, much effort has been invested in
attempts to characterize the “strain properties”of the agent
affecting cows and humans. Because the molecular sub-
strate underlying the nature of prion strains (which are
inheritable phenotypic traits that can be reproduced upon
serial passage through experimental animals) is not known,
strain typing of prion has to rely on surrogate markers.
Two such markers have proved particularly useful.One is
the distribution of vacuoles in the brain of affected ani-
mals: some strains will mainly target, for example, the
cortical cerebral ribbon,while others will predominantly
Table I. Incidence of new-variant Creutzfeldt-Jakob disease (nvCJD) in the
United Kingdom since 1985. Although data for 2000 were
incomplete at the time of writing, the incidence of nvCJD
appears to have surpassed that of sporadically occurring
Creutzfeldt-Jakob disease (sCJD) for the first time.
9
*Including probable deaths awaiting postmortem results, and liv-
ing sufferers of probable nvCJD.
**Including hereditary and iatrogenic cases (not shown here).
Reproduced from reference 9: 
http://www.doh.gov.uk/cjd/stats/sept00.htm.
Copyright © 2000, Department of Health, UK.
Year sCJD  nvCJD* Total** 
1985 26 28 
1986 26  26 
1987 23  24 
1988 22  24 
1989 28  32 
1990 28  33 
1991 32  36 
1992 43  51 
1993 38  46 
1994 51  59 
1995 35  3  47 
1996 40  10  60 
1997 59  10  80 
1998 63  18  88 
1999 61  14  83 
2000 25  27  52 
Table II. Diagnostic criteria for new-variant Creutzfeldt-Jakob disease
(nvCJD).
9
MRI, magnetic resonance imaging; sCJD, sporadically occurring
Creutzfeldt-Jakob disease.
Reproduced from reference 9:
http://www.doh.gov.uk/cjd/stats/sept00.htm.
Copyright © 2000, Department of Health, UK.
I    Progressive neuropsychiatric disorder
  Duration of illness >6 months
  Routine investigations do not suggest an alternative diagnosis
  No history of potential iatrogenic exposure 
II   Early psychiatric symptoms 
  Persistent painful sensory symptoms 
  Ataxia
  Myoclonus or chorea or dystonia
  Dementia 
III   Electroencephalogram does not show the typical appearance
of sCJD (or no electroencephalogram performed)
  Bilateral pulvinar high signal on MRI scan 
IV   Positive tonsil biopsyBasic research
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affect the midbrain.
19The BSE prion strain was shown to
virulently and consistently attack the dorsal medulla and
the superior colliculus (part of the optical pathway).
20 A
careful study of these parameters yielded the disquieting
result that BSE prions extracted from the brains of
affected cows and nvCJD prions derived from the brains
of British patients do indeed produce the same lesional
patterns when transmitted to panels of susceptible mice.
20-22
The second marker for strain typing of prions comes from
the analysis of the biochemical properties of the disease-
associated prion protein recovered from the brain of cat-
tle and humans.These studies take advantage of the fact
that different steric conformations (which, according to
the most popular current hypothesis,account for the phe-
notypic strain properties) will expose different sites of
the protein to the action of proteolytic enzymes,which,in
turn,can be identified by the different molecular weights
of the resulting fragments.When used in conjunction with
the ratio of diglycosylated to monoglycosylated prion pro-
tein—another parameter that appears to correlate with
strain properties—these traits were again indistinguish-
able between BSE and human nvCJD prions.
23,24
A third line of argument relating BSE and human
nvCJD concerns the epidemiology of the disease. To
date,the total number of definite and probable cases of
nvCJD amounts to 82 in the United Kingdom, 1 in Ire-
land,and 2 in France.
25Assuming that the quality of the
epidemiological surveillance is similar in these countries
and in the rest of Europe, which has not reported cases
of nvCJD, the conclusion that its incidence correlates
with the prevalence of BSE is unavoidable.
One of the most powerful arguments for the pathogen-
esis comes from primate studies.In a classic experiment,
the French group of Lasmézas and colleagues inocu-
lated brain extracts from BSE-affected cows into
cynomolgus macaques. After approximately 3 years,
all inoculated primates (2 adults and 1 infant) devel-
oped spongiform encephalopathy.The histopathological
appearance of the disease was identical to that of nvCJD
and included the characteristic “florid plaques,” which
are never present in sCJD,but have been recognized in
every single case of nvCJD.
26
As impressive as the above list of arguments may seem,
there is no denying that each is phenomenological rather
than causal.Distribution of histopathological lesions,as
well as morphology of plaque deposits, is certainly way
downstream of the molecular events responsible for
prion strain specificity.Measurements of the “glycotype
ratio” may be more directly related to the essence of
strains,but there is still no way to tell whether they may
represent mere surrogate markers.
It is desirable to measure the conformation of the disease-
associated prion protein in a more direct way. Some
inroads have been made toward that goal with a method
that exploits the relative affinities of antibodies against
the normal mammalian prion protein (anti-PrP
C),
27,28 but to
our knowledge this possibility is, so far, restricted to the
differentiation of mouse and hamster prion proteins,and
has not yet been applied to investigating BSE and nvCJD.
The question on everybody's mind,however,is how the
numbers of nvCJD victims will change in the future.As
terrible as the disease has been for the patients affected
thus far, we have not yet seen a large-scale epidemic.
Although many mathematical models have been gen-
erated,
29,30 the number of cases that have been identified
so far is still too small to gain any certainty about future
developments. That the number of cases diagnosed in
the last 12 months amounts to 36 (up from 14 in the 12
months before that) is certainly cause for concern,if not
for alarm.
31 
Another extremely important question relates to the pos-
sible existence of chronic subclinical disease, and the pos-
sibly of a permanent carrier status—in cows as well as in
humans. Evidence that such a carrier status may be pro-
duced by the passage of the agent across species was first
reported by Race and Chesebro,
32,33 and has recently been
confirmed—at least for the passage between hamsters and
mice.
34 Immune deficiency can also lead to a similar situa-
tion in which prions replicate silently in the body, even
when there is no species barrier.
35 These hints may imply
that the problem of animal transmissible spongiform
encephalopathies (TSEs) could be more widespread than
generally assumed,and may call for drastic measures in the
realm of farming.It is not impossible that humans carrying
the agent may transmit it horizontally.
36 The risks associ-
ated with the latter possibility can be met competently only
if knowledge is accrued about the mode of transmission of
the agent and the mechanism by which prions reach the
brain upon peripheral inoculation into extracerebral sites.
The rest of this review article is devoted to analyzing the
progress that has been made in these fields.
The making of prions 
A noncommittal, operational definition
37 says that the
prion is the infectious agent that causes scrapie, BSE,CJD,other TSEs,such as chronic wasting disease of mule
deer and elk,and other less common diseases that affect,
for example, exotic ungulates and captive felids. Obvi-
ously,although this definition is useful in that it facilitates
understanding, it says nothing about the true physical
nature of the agent.A very different definition that has
become rather popular among yeast geneticists centers
around the structural biology of prions.According to this
second definition, prions are proteins that can exist in
at least two different conformations, one of which is
capable of inducing the conversion of further individual
prion molecules from one conformation into the other.
Therefore, prion proteins can serve as true genetic ele-
ments even if they do not contain informational nucleic
acids,in that they are self-perpetuating and heritable.
38
Nineteen years after the original formulation of the
prion hypothesis by Stanley Prusiner (Figure 2), and 4
years after he was awarded the Nobel Prize in 1997,
there continues to be uncertainty about the question of
whether these two definitions coincide in the case of
mammalian prions.One further problem is that all amy-
loids and their precursors would fit the second defini-
tion, yet amyloid proteins themselves do not appear to
be transmissible or infectious in vivo or in cell cultures.
In the last few months,we have witnessed breathtaking
advances in the understanding of prion phenomena in
yeast, and there is no doubt that at least two yeast pro-
teins exist that fulfill the above definition.It is generally
Recent developments in prion diseases - Aguzzi Dialogues in Clinical Neuroscience - Vol 3 . No.1 . 2001
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Figure 2. The “protein only” hypothesis and two popular models for the conformational conversion of normal prion protein PrP
C into disease-asso-
ciated prion protein PrP
Sc. (a) The “refolding” or template assistance model postulates an interaction between exogenously introduced PrP
Sc
and endogenous PrP
C, which is induced to transform itself into further PrP
Sc. A high energy barrier may prevent spontaneous conversion of
PrP
C into PrP
Sc. (b) The “seeding” or nucleation-polymerization model proposes that PrP
C and PrP
Sc are in a reversible thermodynamic equi-
librium. Only if several monomeric PrPSc molecules are mounted into a highly ordered seed, can further monomeric PrP
Sc be recruited and
eventually aggregate to amyloid. Within such a crystal-like seed, PrP
Sc becomes stabilized. Fragmentation of PrP
Sc aggregates increases the
number of nuclei, which can recruit further PrP
Sc and thus results in apparent replication of the agent. Basic research
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believed that the ultimate experiment proving that a
given protein is a prion is “in vitro conversion”:this term
defines a cell-free manipulation by which the nonconta-
gious conformation is transformed into a transmissible
agent. Ideally, this manipulation should occur without
participation of the pathological,transmissible prion,in
order to formally exclude the possibility of cross-conta-
mination.Two recent papers have shown that these con-
ditions can be met in the case of the yeast prions identi-
fied so far,Sup35
39,40 and Ure2p.
41,42 
Disappointingly, no such successes have ever been
reported in the case of mammalian prions, despite the
most intensive of efforts.In vitro conversion of the normal
mammalian prion protein,PrP
C (C for cellular),can yield
a moiety that displays many of the physical and chemical
properties characteristic of the disease-associated prion
protein, PrP
Sc (Sc for scrapie), such as aggregation into
higher-order quasi-crystalline complexes that are bire-
fringent when observed under polarized light (especially
upon staining with amyloid dyes,such as Congo red),for-
mation of fibrils that are identifiable by electron
microscopy,and partial resistance to proteolytic enzymes
as identified by digestion with proteinase K.
43 Intriguingly,
in vitro conversion is subject to a distinct species barrier,
just like “true”spongiform encephalopathies.
44,45
However,the crucial element that is common to the two
definitions mentioned above, and that is absolutely
required for the classification of a protein as a prion, is
transmissibility. None of the experimental procedures
that have been reported thus far have unambiguously
accomplished the transformation of the cellular prion
protein PrP
C into a transmissible agent. There is no
dearth of speculations about why this has not been pos-
sible:the requirement for additional cellular factors dis-
tinct from PrP
C, for example, has been invoked on the
basis of genetic evidence,
46 but has never been proven.
Universal consensus about the nature of the agent will
predictably only be reached once synthetic reconstitu-
tion from noninfectious material will have been achieved.
How prions damage their hosts 
Notwithstanding all the unresolved problems,a number
of important properties of the infectious agent can be
studied,even in the absence of ultimate certainty about
its true physical nature.Perhaps the most obvious ques-
Figure 3. Neuropathological features of transmissible spongiform encephalopathies. Histology and immunohistochemical analysis of frontal cortex
samples of the brain of a patient who died of noncerebral causes (upper row) and a patient suffering from Creutzfeldt-Jakob disease (CJD)
(lower row). Brain sections were stained with hematoxylin-eosin (HE, left panels), with antibodies against glial fibrillary acidic protein (GFAP,
middle panels), and with antibodies against the prion protein (PrP, right panels). Neuronal loss and prominent spongiosis are visible in the
HE stain. Strong proliferation of reactive astrocytes (gliosis) and perivacuolar PrP deposits are detectable in the GFAP and PrP immunostains
of the CJD brain samples.Recent developments in prion diseases - Aguzzi Dialogues in Clinical Neuroscience - Vol 3 . No.1 . 2001
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tion regards what accounts for the exquisite propensity
of prions to damage the central nervous system (CNS),
the only part of the body undergoing histopathologi-
cally and clinically detectable degeneration (Figure 3).
Cellular models of prion disease may prove very useful
for addressing this question. However, prions replicate
inefficiently in most established cell lines.A large num-
ber of studies have been performed with a synthetic pep-
tide obtained from the central region of the PrP
C mole-
cule, which has been shown to spontaneously assemble
into amyloid-like structures. Interestingly, this peptide
can elicit in vitro many reactions of brain cells that
resemble those seen in vivo during the late stages of
prion disease:activation of microglia cells,stimulation of
intermediate filament production by astrocytes, and
even death of neurons,which appears to depend on the
presence of the normal prion protein in target cells.
47,48 
Despite the amount of information that has been
accrued,all of these studies suffer from the fundamental
problem that it is not clear whether the phenomenon
observed in conjunction with exposure of cells to this
small amyloidogenic peptide bear much relevance to
what is happening in vivo during the course of prion
replication—a process that may arguably be very dif-
ferent. Moreover, some of the published data have
recently been challenged.
49
In order to ask the simple question of whether cerebral
accumulation of PrP
Sc in the extracellular space suffices
to damage nerve cells,we have undertaken fetal neuro-
ectodermal transplantation experiments.
50 Histological
analysis of PrP-deficient mice that had been grafted with
brain cells derived from transgenic mice overexpress-
ing PrP
C and subsequently infected with prions indicated
that pathology is confined to the regions of the brain
that express PrP
C. In the surrounding PrP-deficient
brain, no pathological changes could be detected even
though substantial accumulations of pathological PrP
Sc
occurred.
50While the interpretation of this experiment is
liable to certain caveats (most notably the possibility
that a threshold concentration of PrP
Sc is needed for
induction of neurodegeneration and is not attained out-
side the grafted tissue), it is difficult to avoid the con-
clusion that the neuronal cytotoxicity of PrP
Sc is depen-
dent on the expression of cellular PrP
C by target cells.
Why should that be? Perhaps PrP
C acts as a receptor for
PrP
Sc. However, it has never been possible to demon-
strate an affinity between these two moieties. Alterna-
tively, the conversion process of PrP
C into PrP
Sc itself,
rather than exposure to the disease-associated prion
protein,may constitute the primary deleterious event.
The latter possibility has been thoroughly investigated in
a series of elegant papers by Lingappa and coworkers.
These authors have identified an atypical form of PrP
C
that undergoes a peculiar biogenesis (Figure 4).
51-54 Most
cellular PrP
C is secreted into the lumen of the endoplas-
mic reticulum (ER) by virtue of its secretory signal pep-
tide, where it is routed to the cell surface as a glyco-
phosphoinositol-linked membrane-associated protein.
However, a small proportion of PrP
C remains stuck in
the ER membrane as a transmembrane protein.
Depending on their orientation,Lingappa and cowork-
ers have termed these proteins 
CtmPrP and 
NtmPrP (for
carboxy- and amino-terminal transmembrane, respec-
tively).
55,56 By quantifying the production of 
CtmPrP in
pathological conditions, they found that it correlates
very well with the neurodegenerative changes—in fact
much better than the accumulation of PrP
Sc itself.
51,57
These observations formed the basis for the hypothe-
ses that (i) 
CtmPrP is a marker of prion-induced neurode-
generation; and (ii) the conversion process of PrP
C into
PrP
Sc triggers the formation of 
CtmPrP,which,in turn,is an
effector of neurotoxicity.Strong circumstantial evidence
favors the second hypothesis,although the putative sig-
naling pathways involved are still completely obscure.
The neuroinvasion of prions 
In most cases of prion infection of humans and animals,
the port of entry is extraneural.In the case of BSE (and
possibly of nvCJD), exposure is probably oral, while
most iatrogenic cases of CJD have occurred by par-
enteral administration (for example,intramuscular injec-
tion).The mechanism by which prions administered to
the periphery of the body reach the CNS are therefore
of great interest. By analogy with neurotropic viruses,
there may be two main pathways of neuroinvasion.
Many viruses,for example,those causing rabies and her-
pes, exploit the anatomical connections provided by
peripheral nerves, and reach the CNS via axonal trans-
port. Human immunodeficiency virus (HIV), however,
utilizes a totally different mechanism: it reaches cere-
bral microglial cells using a “Trojan horse” mechanism
that involves infection of macrophages.The latter cells
are in equilibrium with perivascular microglia and are
the prime target of HIV infection in the CNS.
What about prions? The available evidence suggests thatBasic research
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Figure 4.  Upper panel: Three-stage model of prion pathogenesis (adapted from reference 51). Stage I represents the formation and accumulation of
disease-associated prion protein PrP
Sc, initiated by either inoculation or spontaneous conversion of a mutated normal prion protein PrP
C into
PrP
Sc. Stage II symbolizes the events involved in generating C-transmembrane prion protein 
CtmPrP (see below), either by an unknown process
involving PrP
Sc (characterized by dashed lines) or by certain mutations within PrP. Two distinct forms of PrP can be made at the endoplasmic
reticulum (ER): one that is fully translocated (
secPrP) and one that is transmembrane. Digestion with proteases of the latter results in two frag-
ments: one is carboxy-terminal derived and glycosylated, the other is amino-terminal–derived and unglycosylated; thus, the first is termed
C-transmembrane PrP (
CtmPrP) with the carboxy-terminus in the ER lumen and the amino-terminus accessible to proteases in the cytosol,
whereas the second is termed N-transmembrane PrP (
NtmPrP) with an opposite conformation. Stage III depicts the hypothetical events involved
in 
CtmPrP-mediated neurodegeneration, possibly involving the exit of 
CtmPrP to a post-ER compartment.
Lower panel: Possible role of 
CtmPrP in cell death (adapted from reference 52): full-length PrP may act as a coreceptor on the cell surface, medi-
ating the juxtaposition of two cell-surface transmembrane molecules A and B. This generates a signal for cell survival in the cytosol. Failure
of 
CtmPrP to bind B could induce cell death by not facilitating the association of A to B. This mechanism also could explain effects of expres-
sion of an amino-terminally truncated PrP
53 as well as the Doppel gene product.
54
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both of these pathways may play a role.A wealth of evi-
dence gathered in the last two decades indicates that pri-
ons are capable of colonizing the immune system; lym-
phocytes
58 and follicular dendritic cells (FDCs)
59 (which
are located in the germinal centers of lymphoid organs)
express sizable amounts of PrP
C. Blättler and colleagues
have shown that extracerebral prion protein is required for
neuroinvasion: Prn-p knockout mice harboring a PrP
C-
expressing graft in their brain
50 consistently develop
spongiform encephalopathy restricted to the neuroecto-
dermal graft upon intracerebral inoculation,
60 but not upon
intraocular,intraperitoneal,or even intravenous adminis-
tration of the infectious agent.
61 At least in the case of
intraocular inoculation, impairment of neuroinvasion is
effected even when a specific transgenic manipulation pre-
vents all antibodies against PrP
C from being generated.
62
Therefore, the absence of PrP
C, rather than an immune
response against prions,prevents spread of the infectious
agent within the body of a PrP
C-deficient mouse.
63
From spleen to brain
The next obvious question relates to the identity of the
cellular compartment that necessitates expression of PrP
C
in order to support neuroinvasion. Reconstitution of the
hematopoietic and lymphopoietic system with stem cells
derived from wild-type or transgenic mice overexpress-
ing PrP
C does not suffice to restore neuroinvasion,
64 imply-
ing that the crucial compartment that needs to express
PrP
C is sessile and cannot be transferred by adoptive bone
marrow reconstitution.
61While the latter,negative results
do not allow for unequivocal identification of the respon-
sible compartment (for which there is a choice of at least
two likely candidates, ie, peripheral nerves
65 and FDCs),
titration experiments indicate that adoptive bone marrow
transfer robustly reconstitutes the capability of the spleen
to accumulate (and perhaps replicate) prions of the Rocky
Mountain Laboratory (RML) strain after intraperitoneal
inoculation.
61 This latter result was unexpected, and may
suggest that hematopoietic cells (perhaps lymphocytes)
may replicate prions,or may be otherwise involved in the
transport of the agent from the site of inoculation to the
spleen.Brown and colleagues have recently reported that,
using a different prion strain called ME7, no accumula-
tion of prions was detected in spleens of 13 PrP
C knockout
mice reconstituted with PrP
C-positive hematopoietic cells
and killed at unspecified “intervals through the incuba-
tion period.”
66 Our laboratory has therefore repeated the
experiments published previously and confirmed their
unambiguous reproducibility in a large-scale study involv-
ing assessment of prion titers and PrP
Sc accumulation at 30,
60,90,120,and 270 days after inoculation in mice (P.Käser
et al,unpublished results).Assuming that the experimen-
tal design of the Zurich and the Edinburgh studies is
indeed comparable,the discrepancy between the Blättler
results and those reported by Brown point to the possibil-
ity that different prion strains exhibit different tropisms for
specific components of the immune system.There may be
precedents for this: BSE prions are hardly detectable in
lymphoid organs (with the possible exception of gut-asso-
ciated lymphoid tissue for a transient period of time),
while nvCJD prions extensively colonize human lymphoid
organs.The identification of the molecular determinants of
such differences in organ tropism may shed light on a basic
mechanism of prion pathogenesis, and is also of prime
public health interest for the reasons detailed above.
Anatomy of prion neuroinvasion
What are the cellular requirements for the lympho-
invasion of prions? This question was addressed by
screening mouse strains with spontaneous and engi-
neered deficiencies in various compartments of the
immune system. From these studies, one clear-cut result
emerged: any genetic defect that impairs the terminal
differentiation of B lymphocytes completely blocks the
colonization of lymphoid organs by prions,as well as the
development of disease in the CNS upon peripheral inoc-
ulation.
67This phenomenon is obviously due to a block of
neuroinvasion, since B-cell–deficient mice display the
same susceptibility to disease as wild-type mice when
inoculated intracerebrally.
67The dependence of neuroin-
vasion on B lymphocytes is absolute:we are not aware of
any experimental design,mouse strain,or prion strain in
which the spread of prions from the periphery to the
CNS is not impaired by the ablation of B lymphocytes.
The necessity for the presence of B cells does not imply
that they are sufficient for neuroinvasion. However, all
attempts to identify additional necessary compartments
have yielded less unambiguous results.A further candi-
date that is most likely required for neuroinvasion is cer-
tainly the FDC. FDCs have long been identified as the
main site of accumulation of PrP
Sc in lymphoid organs.
59
However, experiments aimed at exploring the role of
FDCs in peripheral prion pathogenesis have been less
conclusive.So far,all the published material unanimouslyBasic research
34
indicates that accumulation of prions of intraperitoneally
(IP) inoculated mice can only occur in spleens that have
properly formed germinal centers and immunohisto-
chemically identifiable FDCs: it has proven impossible
to recover prions from spleens of IP inoculated mice defi-
cient in tumor necrosis factor (TNF) receptor-1
(TNFR1)
67 (M.A.Klein et al,unpublished data) or TNF-
α ,
66 none of which contain identifiable FDCs in their
spleens. In the case of the FDC-deficient lymphotoxin β
(LTβ ) knockout mice,
68 splenic infectivity was unfortu-
nately not determined. Moreover, administration of sol-
uble lymphotoxin β receptor (LTβ R) very efficiently pre-
vents the buildup of a splenic prion burden in wild-type
mice,
69 a fact that was later confirmed to also be valid for
the ME7 prion strain for scrapie,
70 despite its many
alleged differences from the RML strain.
On the other hand, neuroinvasion—the development of
brain disease after peripheral challenge—was completely
unaffected in TNFR1
67 and LTβ
68 knockout mice, and
could not even be fully repressed by the LTβ R-Fc treat-
ment.
69,70 Therefore, while the lack of LTβ signaling to
FDCs is likely to account for some of the protection from
peripheral prion inoculation observed in B-cell–deficient
mice,all of the latter results point to an additional role of
B cells in prion neuroinvasion, which is clearly indepen-
dent of PrP expression
71 and must be distinct from
LTβ /TNF signaling to FDCs.Because sympathetic nerve
fibers do not appear to penetrate the germinal centers of
lymphoid organs (M.Glatzel and A.Aguzzi,unpublished
observation),lymphocytes may conceivably play a role in
the migration of prions from FDCs to peripheral nerves.
Prions and blood
Because prions can be detected in lymphoreticular tis-
sues of nvCJD patients,is there a risk of iatrogenic trans-
mission via exposure to blood or tissues derived from
preclinical nvCJD cases,and possibly from contaminated
surgical instruments? Very thorough epidemiological
surveys over two decades have not implicated blood
transfusions or administration of blood products as risk
factors for prion diseases. A small increase in relative
risk for sCJD is associated with a history of surgery of all
kinds,
72 and may indeed be indicative of unrecognized
iatrogenic transmission.
However,the situation may not be as simple for nvCJD.
For one thing, we do not know nearly as much about
the epidemiology and iatrogenic transmissibility of this
new disease as we do about sCJD.What is most unset-
tling is that the distribution of preclinical disease in the
United Kingdom and other countries is totally obscure.
The only available information is a retrospective
immunohistochemical analysis of British appendices and
tonsils
73—a well-meant study,but of limited sensitivity.
Moreover, nvCJD appears to be much more “lymphoin-
vasive”than sCJD.In particular,nvCJD prions can be eas-
ily detected in lymphatic organs such as tonsils and appen-
dix,
15,16,74 a fact that was previously demonstrated to be true
for scrapie,
75-77 but not for sCJD prions.While all the avail-
able evidence points to FDCs as the prion reservoir in
lymphatic organs, splenic lymphocytes of experimentally
inoculated mice can be infected with prions.
78Although
prion infectivity of circulating lymphocytes appear to be at
least two logs lower than that detected in splenic lympho-
cytes,
78 the possibility that circulating lymphocytes may be
in equilibrium with their splenic counterparts calls for cau-
tionary measures.The nature of the latter is matter of con-
troversy:leukodepletion has been advocated,but there is
still no certainty about its efficacy. In addition, even if
blood prion infectivity were to be originally contained in
lymphocytes in vivo, lysis of cells may lead to contamina-
tion with infectious “microparticles,”
78 which may be diffi-
cult to remove by any method, short of ultracentrifuga-
tion.On a more positive note,however,many of the virus
removal steps involved in the manufacturing of stable
blood products have some positive effects on prion
removal.Therefore,the latter possibility can be regarded as
a worst-case scenario.
A last consideration applies to secondary prophylaxis.
Given the very large amount of infectious BSE material
that has entered the human food chain,it is possible that
many individuals harbor preclinical nvCJD. It is imper-
ative and urgent to develop strategies that will help con-
trol spread of the agent and that will hopefully prevent
the clinical outbreak of symptoms in these persons, and
some promising approaches have been identified.
80,81 Pos-
sible targets for the interference with neuroinvasion are
rate-limiting processes that control prion replication
within the infected individual.In light of the knowledge
discussed above, treatments that target the neuroim-
mune interface of prion replication and neuroinvasion
82
continue to represent a promising area for research
aimed at postexposure prophylaxis.❏
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